Posts Tagged: "Neptune"

On Thursday, October 5th, a final written decision issued by the Patent Trial and Appeal Board (PTAB) upheld a series of 22 claims from a patent owned by Indianapolis, IN-based drugmaker Eli Lilly & Company (NYSE:LLY). This decision ends an inter partes review (IPR), which was initially petitioned by Chicago, IL-based generic pharmaceutical firm Neptune Generics to challenge a patent covering Alimta, a drug approved by the U.S. Food and Drug Administration (FDA) as a treatment for patients with advanced nonsquamous non-small cell lung cancer (NSCLC). Although sales of Alimta have dropped in recent months, the cancer treatment remains an important part of Eli Lilly’s portfolio.